CD8A and primary cutaneous T-cell non-Hodgkin lymphoma: CBCL and CTCL patients who responded had an increase in frequency of CD8+ cells and TIA-1+ cells, indicative of an immune response which is a critical component in the antitumor response in lymphoma.